Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.40 |
| ▸ | TUBB | P07437 | 2/20 | 0.40 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.40 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.40 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.40 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.40 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.40 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.40 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.40 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.40 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.40 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.40 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.40 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6715720 | 0.82 | L3MBTL1 (0.48) | ACHEMAPTCYP3A4CA9L3MBTL1 | |
| SCHEMBL2783924 | 0.78 | MAPT (0.47) | ACHEMAPTCYP3A4CA9L3MBTL1 | |
| SCHEMBL11963646 | 0.78 | MAPT (0.47) | ACHEMAPTCYP3A4CA9L3MBTL1 | |
| SCHEMBL28134390 | 0.78 | ACHE (0.45) | ACHEMAPTCYP3A4CA9L3MBTL1 | |
| SCHEMBL11963636 | 0.78 | MAPT (0.47) | ACHEMAPTCYP3A4CA9L3MBTL1 | |
| SCHEMBL5786402 | 0.77 | ACHE (0.43) | ACHEMAPTCYP3A4CA9L3MBTL1 | |
| SCHEMBL20400672 | 0.77 | ACHE (0.43) | ACHEMAPTCYP3A4CA9L3MBTL1 | |
| SCHEMBL10810091 | 0.77 | GAA (0.35) | ACHEERN1ALDH1A1GAAMEN1 | |
| SCHEMBL20177381 | 0.76 | L3MBTL1 (0.47) | ACHEMAPTCYP3A4CA9L3MBTL1 | |
| SCHEMBL10808988 | 0.75 | GAA (0.43) | MAPTERN1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050065213-A1 | Combretastatin a-4 derivatives having antineoplastic activity | LAWRENCE NICHOLAS JAMES (GB) | 2005-03-24 | — | — | US | disclosed |
| EP-1444190-A1 | COMBRETASTATIN A-4 DERIVATIVES HAVING ANTINEOPLASTIC ACTIVITY | Cancer Research Technology Limited (GB) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003040077-A1 | COMBRETASTATIN A-4 DERIVATIVES HAVING ANTINEOPLASTIC ACTIVITY | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065213-A1 | Combretastatin a-4 derivatives having antineoplastic activity | AURKA, AURKB, HDAC4 | ACHE 2647/4885MAPT 2531/4885CYP3A4 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.